CLAIMS

We claim:

1. A composition comprising: Brassica oleracea 22.95±11%, Daucus carota 32.78±15%, Apium graveolens L. 24.59±12%, Petroselinum crispum <1±0.5%, Spinacia oleracea L 11.47±5%, Beta vulgaris 8.19±4%, aloe vera <1±0.5%, and honey <1±0.5%.

2. The composition of Claim 1, further comprising Lycopersicon esculentum.

3. The composition of Claim 2 further comprising Citrullus vulgaris.

4. The composition of Claim 3 further comprising Citrus aurantifolia.

5. The composition of Claim 4 further comprising Cymbopogon sp.

6. The composition of Claim 1 further comprising Lycopersicon esculentum, Citrullus vulgaris, and Citrus aurantifolia.

7. A dietary supplement comprising an effective amount of a composition of Claim 1.

8. The composition of any of Claims 1-7, wherein the form of the composition is selected from the group consisting of an orally administered form, an injectable form, and an externally applicable form.

9. The composition of Claim 8, wherein the composition is in the orally administered form and the orally administrable form is selected from a group consisting of a juice, a tablet, a powder, a suspension, an emulsion, a capsule, a granule, a troche, a pill, a liquid, a spirit, a syrup, and a limonade.

10. The composition of Claim 8, wherein the composition is in the injectable form and the injectable form is selected from the group consisting of a liquid, a suspension, and a solution.

11. The composition of Claim 8, wherein the composition is in the externally applicable form and the externally applicable form is selected from the group consisting of an ointment, a liquid, a powder, a plaster, a suppository, an aerosol, a liniment, a lotion, an enema, and an emulsion.

12. The pharmaceutical composition comprising a pharmaceutically effective amount of a composition of claim 1 and a pharmaceutically acceptable carrier.

13. The pharmaceutical composition of Claim 12, wherein the form of the composition is selected from a group consisting of an orally administered form, an injectable form, and an externally applicable form.

14. The pharmaceutical composition of Claim 13, wherein the composition is in the orally administered form and the orally administrable form is selected from a group consisting of a juice, a tablet, a powder, a suspension, an emulsion, a capsule, a granule, a troche, a pill, a liquid, a spirit, a syrup, and a limonade.

15. The pharmaceutical composition of Claim 13, wherein the composition is in the injectable form and the injectable form is selected from the group consisting of a liquid, a suspension, and a solution.

16. The pharmaceutical composition of Claim 12, wherein the composition is in the externally applicable form and the externally applicable form is selected from the group consisting of an ointment, a liquid, a powder, a plaster, a suppository, an aerosol, a liniment, a lotion, an enema, and an emulsion.

17. The composition of any of Claims 1-6, which is administered as a dietary supplement to facilitate normal physiologic function and growth.

18. The composition of any of Claims 1-6, when taken at an effective dose over a period of time, reduces or eliminate tumor burden in liver cancer.

19. The composition of any of Claims 1-6, when taken at an effective dose over a period of time, aids and expedites liver regeneration.

20. The composition of any of Claims 1-6, when taken at an effective dose over a period of time, prevents development of liver cancer in predisposed patients with liver cirrhosis.

21. The composition of any of Claims 1-6, when taken at an effective dose over a period of time, prevents development of liver cancer in predisposed patients with viral and non-viral hepatitis.

22. The composition of any of Claims 1-6, when taken at an effective dose over a period of time, is effective in treating viral hepatitis by lowering the liver enzymes AST and ALT and lowering the viral hepatitis load found in the body.

23. A method of treatment of liver cancer comprising administering the composition of any of Claims 1-6 in combination with other known, standard or experimental treatment protocols for liver cancer.

24. A method of treatment of liver cancer comprising administering the composition of any of Claims 1-6 as a bridging therapy to down-grade the size of inoperable liver cancers to a resectable or transplantable size.

25. A method of treatment of liver damage caused by chemoembolization comprising administering the composition of any of Claims 1-6 to aide in liver regeneration for normal liver parenchyma damaged in hepatic chemoembolization.

26. A method for treatment of a disorder of the hepatobiliary system comprising administering the composition of any of Claims 1-6.

27. The composition and its methods of use disclosed herein may be used in combination with other known, standard or experimental treatment protocols for other cancers.

28. The composition and its methods of use disclosed herein may be used in combination with other known, standard or experimental preventative protocols for liver and other cancers.

29. A method for the treatment of liver cancer comprising oral administration of the composition in any of Claims 1-6.

30. A method for the treatment of cirrhosis of the liver comprising oral administration of the composition in any of Claims 1-6.

31. A method for the treatment of hepatitis of the liver comprising oral administration of the composition in any of Claims 1-6.